Clinical pharmacogenetics in pediatric patients.
Pediatric pharmacogenetic studies have the potential to improve the quality of medical care for children. The pediatric population presents a unique pharmacogenetic challenge as children have the additional complexity of ontological phenotypes that impact their drug response. Prescribing medications in children has historically been largely empirical, but utilization of pharmacogenetic information will allow pediatricians to gain key information regarding which patients are best suited for a particular therapeutic agent and which patients may be at risk for serious potentially life-threatening complications from standard treatment regimens. Although large, prospective, multisite investigators are still needed, we illustrate selective clinical examples of the pharmacogenetics for treatment of transplantation, asthma, leukemia and attention-deficit hyperactivity disorder in pediatric patients.
Husain
Anwar
A
University of Louisville, Department of Pharmacology & Toxicology and James Graham Brown Center, School of Medicine, Louisville, KY, USA.
Loehle
Jennifer A
JA
Hein
David W
DW
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D001249:Asthma / Q000235:genetics; D001289:Attention Deficit Disorder with Hyperactivity / Q000235:genetics; D002648:Child; D004358:Drug Therapy / Q000379:methods* / Q000592:standards; D006801:Humans; D007938:Leukemia / Q000235:genetics; D016377:Organ Transplantation; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1